Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond
The model's full reasoning — Q3 2016 call → NOWe need to determine if management expresses clear conviction that the business is stepping up to a meaningfully higher level over coming quarters, and if that conviction is grounded in concrete things already in hand or happening, not just market conditions. Let's analyze the transcript. Management discusses economic outlook, expects modest recovery next year (GDP 2% vs 1.6% this year). They talk about loan growth expectations: "we are expecting GDP to grow around 2% next year and that should be equivalent to around 4% real growth terms of total loans, in nominal terms around 6% to 7%." That's a projection based on macro recovery. They mention retail segment driving growth. But is there a clear conviction about a step-up? They say "we are confident that we should begin to see a better economic activity and this should help loan growth." That's more about macro recovery. They also talk about achievements: launched new retail banking website, new foreign currency platform, etc. But do they say these will lead to a meaningfully higher level of business? They mention "these innovations... premiered us to be recognized as the best consumer digital bank" but not a step-up in results. They discuss cost control and efficiency. They say "we are confident that our permanent focus on cost control and new projects are aimed at improving customer service and optimizing internal processes should bear fruit, maintaining expense growth lower than customer income and in the medium term improve efficiency levels." That's about efficiency, not a step-up in business. They also mention "we have continued growing in that market" (upper-income) but not a step-up. The overall tone is steady continuation, with modest growth expectations tied to macro recovery. They don't express a clear conviction that the business is stepping up to a meaningfully higher level. They expect loan growth of 6-7% nominal, which is not a dramatic step-up. They also mention NPLs may rise moderately. Thus, the answer is NO. The conviction is not clearly stated, and the evidence is not concrete in-hand but rather projections based on macro recovery. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.